...stroke patients worldwide each year. Figure: NoNO selectively targets toxic NMDA receptor signaling in stroke NoNO Inc....
...stroke,” said Tymianski. NoNO launched in 2003. Rather than use standard rat models of stroke, NoNO...
...secondary endpoints. Table: Clinical Results of NoNO Phase III Nerinetide Trial Phase III data from NoNO Inc.’s...

...peptides were not optimized for cell-specific targeting or intracellular localization. According to BioCentury’s BCIQ database, NoNO Inc....
...and Xigen S.A. are the only two companies with HIV tat-based products in the clinic. NoNO’s...
...et de la Recherche Médicale (INSERM), Paris, France Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. NoNO Inc....

...evaluate 2.6 mg/kg IV NA-1 in about 1,120 patients who are candidates for endovascular revascularization. NoNo Inc....
...index and mRS and mortality rate over 90 days Status: Phase III started Milestone: NA Julian Zhu NoNO Inc. Discs...

...start Phase I testing with the human IgM antibody that binds non-POU domain containing octamer-binding (NONO...

...activity in Phase II testing or earlier, including three that specifically target the NMDA pathway. NoNO Inc....
...South San Francisco, Calif. Global Neurotech (GNT) Pharma Co. Ltd. , Yongin-si, South Korea NoNO Inc....

...with our dimeric approach," said CEO Robert Tansley. NA-1 , a monomeric PSD95 inhibitor from NoNO Inc....
...animal models of pain. According to Tansley, NoNo's compound binds to only one PDZ domain. NoNo...
...higher affinity for PSD95 and a substantially longer half-life in human serum in vitro than NoNo's...

...Toronto-based NoNO Inc. has become the first company to show that macaque models have the potential to...
...such models have largely precluded their use, said Michael Tymianski, cofounder, president and CEO of NoNO...
...the hospital's Toronto Western Research Institute . Previous Tymianski-led teams showed the neuroprotective effects of NoNO's...

...by NoNo Inc., which licensed the findings, includes clinical trials of NA-1 to treat ischemic stroke. NoNO...
...hemorrhage. SciBX 5(10); doi:10.1038/scibx.2012.266 Published online March 8, 2012 Macaque models and NA-1 patented by NoNo...

...into cancer cells. PAT-LM1 is a preclinical human antibody that binds non-POU domain containing octamer-binding (NONO...